SCHEMBL7365836

SCHEMBL7365836

CCOC(=O)C1(S(=O)(=O)OC)CCCN(Cc2ccccc2)C1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 7/20 0.61
CYP3A4 P08684 4/20 0.61
CYP2C9 P11712 2/20 0.61
CYP2C19 P33261 2/20 0.61
GAA P10253 3/20 0.58
KDM4E B2RXH2 1/20 0.58
ALDH1A1 P00352 6/20 0.57
KMT2A Q03164 4/20 0.57
MEN1 O00255 3/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
LMNA P02545 3/20 0.54
HTT P42858 2/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
TSHR P16473 2/20 0.52
POLB P06746 2/20 0.51
PKM P14618 1/20 0.51
CYP1A2 P05177 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL567927 0.80 KDM4E (0.63) CYP2D6CYP3A4CYP2C9CYP2C19GAA
SCHEMBL567928 0.80 KDM4E (0.63) CYP2D6CYP3A4CYP2C9CYP2C19GAA
SCHEMBL20502739 0.80 KDM4E (0.63) CYP2D6CYP3A4CYP2C9CYP2C19GAA
SCHEMBL24094559 0.76 CYP3A4 (0.61) CYP2D6CYP3A4CYP2C9CYP2C19GAA
SCHEMBL13744178 0.74 CYP3A4 (0.59) CYP2D6CYP3A4CYP2C9CYP2C19GAA
SCHEMBL13118614 0.74 LMNA (0.65) CYP2D6CYP3A4CYP2C9CYP2C19GAA
SCHEMBL7372315 0.74 MMP1 (0.65) CYP2D6CYP3A4CYP2C9CYP2C19ALDH1A1
SCHEMBL9234554 0.74 KDM4E (0.56) CYP2D6CYP3A4CYP2C9CYP2C19GAA
SCHEMBL13398553 0.74 GAA (0.67) GAAKDM4EALDH1A1KMT2AMEN1
SCHEMBL4503126 0.74 KMT2A (0.62) CYP2D6CYP3A4CYP2C9CYP2C19GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020099035-A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives WYETH HOLDINGS CORPORATION 2002-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099035-A1 Method for preparing alpha-sulfonyl hydroxamic acid derivatives MMP25, ADAMTS5, MMP9 CYP2D6 951/4885CYP3A4 1112/4885CYP2C9 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.